Malcolm LloydSmith - Neurocrine Biosciences Chief Regulatory Officer
| NBIX Stock | USD 131.74 2.92 2.17% |
Executive
Mr. Malcolm LloydSmith serves as Chief Regulatory Officer of Neurocrine Biosciences, Inc. He was appointed Chief Regulatory Officer in September 2014 and is responsible for regulatory affairs and quality assurance. Prior to joining Neurocrine, Mr. LloydSmith served at Cadence Pharmaceuticals, Inc. as Senior Vice President, Regulatory Affairs, Quality and Clinical from August 2012 to September 2014, and previously as Senior Vice President, Regulatory Affairs and Quality Assurance from August 2008. Mr. LloydSmith served as Vice President and Head of Global Regulatory Affairs for Elan Pharmaceuticals, Inc. from September 2003 to August 2008, after having served in the United Kingdom as its Vice President, International Regulatory Affairs from March 2002 to August 2003. Previously, Mr. LloydSmith served in various positions of increasing responsibility with DuPont Pharmaceuticals in Germany, Switzerland, USA and UK. Mr. LloydSmith holds a B.Sc. in Pharmacology from the University of Leeds and a M.Sc. in Pharmacological Biochemistry from Hatfield Polytechnic. since 2014.
| Age | 62 |
| Tenure | 10 years |
| Address | 12780 El Camino Real, San Diego, CA, United States, 92130 |
| Phone | 858 617 7600 |
| Web | https://www.neurocrine.com |
Neurocrine Biosciences Management Efficiency
The company has return on total asset (ROA) of 0.0878 % which means that it generated a profit of $0.0878 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1268 %, meaning that it created $0.1268 on every $100 dollars invested by stockholders. Neurocrine Biosciences' management efficiency ratios could be used to measure how well Neurocrine Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.08 in 2024. Return On Capital Employed is likely to rise to 0.10 in 2024. At this time, Neurocrine Biosciences' Asset Turnover is fairly stable compared to the past year.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sandra Coombs | Alkermes Plc | N/A | |
| Gaozhong Zhu | Eagle Pharmaceuticals | N/A | |
| Blair Jackson | Alkermes Plc | 51 | |
| Samuel Parisi | Alkermes Plc | 49 | |
| Jana Noeldeke | Ironwood Pharmaceuticals | N/A | |
| Max Reinhardt | Pacira Pharmaceuticals | 53 | |
| Lisa Wilson | Eagle Pharmaceuticals | N/A | |
| Richard Scranton | Pacira Pharmaceuticals | 51 | |
| Jennifer Larson | Deciphera Pharmaceuticals LLC | N/A | |
| Todd MBA | Supernus Pharmaceuticals | N/A | |
| Jason Vaughn | Avadel Pharmaceuticals PLC | N/A | |
| Krista Davis | ANI Pharmaceuticals | 50 | |
| Steven Krill | Eagle Pharmaceuticals | 56 | |
| Angie Woods | Avadel Pharmaceuticals PLC | N/A | |
| Matthew MD | Deciphera Pharmaceuticals LLC | 68 | |
| Jerad Seurer | Avadel Pharmaceuticals PLC | N/A | |
| Stephen Schiavo | Alkermes Plc | N/A | |
| Reed McClung | Eagle Pharmaceuticals | N/A | |
| Christopher Mutz | ANI Pharmaceuticals | 52 | |
| George Gorman | Evotec SE ADR | 65 | |
| Volker Braun | Evotec SE ADR | N/A | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0878 |
Neurocrine Biosciences Leadership Team
Elected by the shareholders, the Neurocrine Biosciences' board of directors comprises two types of representatives: Neurocrine Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neurocrine. The board's role is to monitor Neurocrine Biosciences' management team and ensure that shareholders' interests are well served. Neurocrine Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neurocrine Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Mollica, Independent Director | ||
| George Morrow, Director | ||
| Matthew Abernethy, Chief Officer | ||
| Richard Pops, Independent Director | ||
| Eric Benevich, Chief Commercial Officer | ||
| William Rastetter, Independent Chairman of the Board | ||
| Darin Lippoldt, Chief Legal Officer | ||
| Alfred Sandrock, Director | ||
| Jude Onyia, Chief Officer | ||
| Matt Abernethy, CFO | ||
| Navjot Rai, IR Contact Officer | ||
| Darin Esq, Chief Secretary | ||
| Bill Aurora, Vice President - Medical Affairs | ||
| David Boyer, Chief Officer | ||
| Christopher OBrien, Chief Medical Officer | ||
| Stephen Sherwin, Independent Director | ||
| Julie Cooke, Chief People Officer | ||
| DavidAlexandre Gros, President COO | ||
| Eiry Roberts, Chief Medical Officer | ||
| Corinne Nevinny, Independent Director | ||
| Dimitri Grigoriadis, Chief Research Officer | ||
| Haig Bozigian, Chief Devel. Officer | ||
| Kyle Gano, Chief Business Development Officer | ||
| Gary Lyons, Independent Director | ||
| Timothy Coughlin, CFO, Principal Accounting Officer and VP | ||
| Jane Sorensen, Investor Relations Officer | ||
| Malcolm LloydSmith, Chief Regulatory Officer | ||
| Eiry MD, Chief Officer | ||
| Kevin Gorman, CEO and President and Director | ||
| Ingrid Delaet, Chief Officer |
Neurocrine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neurocrine Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0878 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 12.83 B | ||||
| Shares Outstanding | 100.58 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 94.39 % | ||||
| Number Of Shares Shorted | 2.43 M | ||||
| Price To Earning | 202.90 X |
Neurocrine Biosciences Investors Sentiment
The influence of Neurocrine Biosciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Neurocrine. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Neurocrine Biosciences' public news can be used to forecast risks associated with an investment in Neurocrine. The trend in average sentiment can be used to explain how an investor holding Neurocrine can time the market purely based on public headlines and social activities around Neurocrine Biosciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Neurocrine Biosciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Neurocrine Biosciences' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Neurocrine Biosciences' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Neurocrine Biosciences.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Neurocrine Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Neurocrine Biosciences' short interest history, or implied volatility extrapolated from Neurocrine Biosciences options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Neurocrine Stock analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.648 | Earnings Share 2.46 | Revenue Per Share 19.315 | Quarterly Revenue Growth 0.25 | Return On Assets 0.0878 |
The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.